GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Fatty Liver Disease/Late-Night Eating Is Associated With More MASLD and Cirrhosis: CGH | October 2026
1

Late-Night Eating Is Associated With More MASLD and Cirrhosis: CGH | October 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated October 1, 2026

What Did the Study Find?

Investigators analysed nearly 200,000 participants from the Nurses’ Health Study, Nurses’ Health Study II and Health Professionals Follow-Up Study. Late-night eating was defined from self-reported consumption after dinner or after going to bed and was compared with not reporting this behaviour.

Across follow-up, researchers documented 4,477 incident MASLD cases and 312 incident cirrhosis cases. After multivariable adjustment for metabolic, dietary and lifestyle factors, late-night eating was associated with approximately 31% higher MASLD risk (adjusted HR 1.31; 95% CI 1.24–1.39) and 28% higher cirrhosis risk (adjusted HR 1.28; 95% CI 1.02–1.62). These are relative—not absolute—risk increases. Meal timing was self-reported, liver outcomes were not uniformly imaging- or biopsy-defined, and residual confounding by sleep, shift work or other behaviours remains possible. pubmed.ncbi.nlm.nih.gov

Why Does It Matter?

The large longitudinal dataset strengthens the signal that circadian eating patterns may contribute independently to metabolic liver risk. It supports asking about meal timing during lifestyle assessment, but does not establish a therapeutic fasting interval or prove that changing eating time prevents MASLD.

GastroAGI Takeaway

Earlier, consistent meal timing is reasonable low-risk counselling, but late-night eating should be treated as a modifiable risk marker—not yet as a proven causal target.

Related Q&A

02

Resmetirom Benefits Are Confirmed in the Approved F2–F3 MASH Population: Alimentary Pharmacology & Therapeutics | October 2026 issue

What Did the Study Find? This analysis restricted MAESTRO-NASH to 917 patients with biopsy-confirmed F2 or F3 fibrosis, aligning the trial population with the clinical indication for resmetirom....

03

Zabopegdutide Produces Rapid Liver-Fat Reduction in MASLD/MASH—but GI Toxicity Is Frequent: The Lancet Gastroenterology & Hepatology | October 2026

What Did the Study Find? This 12-centre US trial randomised 67 adults with overweight or obesity and MASLD/MASH to once-weekly zabopegdutide—DD01, a dual GLP-1/glucagon-receptor agonist—or placebo. Seventy-eight per...

04

EASL–EASD–EASO 2026: 15 Key Takeaways for Resmetirom and Semaglutide in MASH: Journal of Hepatology | September 2026

MASH pharmacotherapy is now recommended for F2–F3 disease. Adults with non-cirrhotic MASH and significant/advanced fibrosis (F2–F3) should be considered for resmetirom or semaglutide, always alongside lifestyle and cardiometabolic...

05

Lean MASLD: Normal Weight Does Not Mean Low Liver Risk: JAMA | September 2026

What Did the Study Find? This large Global MASLD study evaluated 18,326 patients with biopsy-confirmed MASLD across 41 countries, including 1,224 patients (6.7%) classified as lean by BMI....

06

CagriSema vs Tirzepatide: A New Twist in the Incretin–Amylin Race: Novo Nordisk | September 2026

What Did the Study Find? The phase III REIMAGINE 5 trial compared once-weekly CagriSema 1.0 mg/1.0 mg with tirzepatide 5 mg in adults with type 2 diabetes inadequately...

07

MASH Pharmacotherapy Enters Clinical Practice: Resmetirom or Semaglutide—Who Gets What?: Gut | September 2026

What Does This Update Add? With resmetirom and semaglutide now available for non-cirrhotic MASH with significant F2–F3 fibrosis, this international expert panel provides a practical framework for moving...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer